Veronica Fagerholm
Research Subjects
Veronica Fagerholm has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Erkki Tupala
Departments of Forensic Psychiatry and Clinical Physiology, University of Kuopio, Kuopio, Finland
1 shared publication- Jari Tiihonen
Karolinska Institutet
1 shared publication Jarmo Hietala
Department of Psychiatry, University of Turku, Turku, Finland
1 shared publicationJohanna Rokka
Turku PET Centre, Turku, Finland
1 shared publicationJukka Sallinen
Orion Corporation, Orion Pharma, Turku, Finland
1 shared publicationLeena Nyman
Orion Corporation, Orion Pharma, Turku, Finland
1 shared publication
Latest Publications
- 1 July 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 154 (6) , 1287-1296
α2A‐Adrenoceptor antagonism increases insulin secretion and synergistically augments the insulinotropic effect of glibenclamide in mice
Background and purpose: The imidazoline‐type α2‐adrenoceptor antagonists (±)‐efaroxan and phentolamine increase insulin secretion and reduce blood glucose levels. It is not known whether they act by antagonizing pancreatic β‐cell α2‐adrenoceptors or by α2‐adrenoceptor‐independent mechanisms. Many imidazolines inhibit the pancreatic β‐cell KATP channel, which is the molecular target of sulphonylurea drugs used in the treatment of type II diabetes. To investigate the mechanisms of action of (±)‐efaroxan and phentolamine, α2A‐adrenoceptor knockout (α2A‐KO) mice were used.Experimental approach: Effects of (±)‐efaroxan, 5 mg kg−1, and phentolamine, 1 mg kg−1, on blood glucose and insulin levels were compared with those of the non‐imidazoline α2‐adrenoceptor antagonist [8aR,12aS,13aS]‐5,8,8a,9,10,11,12,12a,13,13a‐decahydro‐3‐methoxy‐ 12‐(ethylsulphonyl)‐6H‐isoquino[2,1‐g][1,6]naphthyridine (RS79948‐197), 1 mg kg−1, and the sulphonylurea glibenclamide, in α2A‐KO and control (wild type (WT)) mice.Key results: In fed WT mice, (±)‐efaroxan, phentolamine and RS79948‐197 reduced blood glucose and increased insulin levels. Fasting abolished these effects. In fed α2A‐KO mice, (±)‐efaroxan, phentolamine and RS79948‐197 did not alter blood glucose or insulin levels, and in fasted α2A‐KO mice, blood glucose levels were increased. Glibenclamide, at a dose only moderately efficacious in WT mice (5 mg kg−1), caused severe hyperinsulinaemia and hypoglycaemia in α2A‐KO mice. This was mimicked in WT mice by co‐administration of RS79948‐197 with glibenclamide.Conclusions and implications: These results suggest that (±)‐efaroxan and phentolamine increase insulin secretion by inhibition of β‐cell α2A‐adrenoceptors, and demonstrate a critical role for α2A‐adrenoceptors in limiting sulphonylurea‐induced hyperinsulinaemia and hypoglycaemia.British Journal of Pharmacology (2008) 154, 1287–1296; doi:10.1038/bjp.2008.186; published online 19 May 2008
- 1 July 2008
- Published by Wiley in British Journal of Pharmacology
- Vol. 154 (6) , 1287-1296
α2A‐Adrenoceptor antagonism increases insulin secretion and synergistically augments the insulinotropic effect of glibenclamide in mice
Background and purpose: The imidazoline‐type α2‐adrenoceptor antagonists (±)‐efaroxan and phentolamine increase insulin secretion and reduce blood glucose levels. It is not known whether they act by antagonizing pancreatic β‐cell α2‐adrenoceptors or by α2‐adrenoceptor‐independent mechanisms. Many imidazolines inhibit the pancreatic β‐cell KATP channel, which is the molecular target of sulphonylurea drugs used in the treatment of type II diabetes. To investigate the mechanisms of action of (±)‐efaroxan and phentolamine, α2A‐adrenoceptor knockout (α2A‐KO) mice were used.Experimental approach: Effects of (±)‐efaroxan, 5 mg kg−1, and phentolamine, 1 mg kg−1, on blood glucose and insulin levels were compared with those of the non‐imidazoline α2‐adrenoceptor antagonist [8aR,12aS,13aS]‐5,8,8a,9,10,11,12,12a,13,13a‐decahydro‐3‐methoxy‐ 12‐(ethylsulphonyl)‐6H‐isoquino[2,1‐g][1,6]naphthyridine (RS79948‐197), 1 mg kg−1, and the sulphonylurea glibenclamide, in α2A‐KO and control (wild type (WT)) mice.Key results: In fed WT mice, (±)‐efaroxan, phentolamine and RS79948‐197 reduced blood glucose and increased insulin levels. Fasting abolished these effects. In fed α2A‐KO mice, (±)‐efaroxan, phentolamine and RS79948‐197 did not alter blood glucose or insulin levels, and in fasted α2A‐KO mice, blood glucose levels were increased. Glibenclamide, at a dose only moderately efficacious in WT mice (5 mg kg−1), caused severe hyperinsulinaemia and hypoglycaemia in α2A‐KO mice. This was mimicked in WT mice by co‐administration of RS79948‐197 with glibenclamide.Conclusions and implications: These results suggest that (±)‐efaroxan and phentolamine increase insulin secretion by inhibition of β‐cell α2A‐adrenoceptors, and demonstrate a critical role for α2A‐adrenoceptors in limiting sulphonylurea‐induced hyperinsulinaemia and hypoglycaemia.British Journal of Pharmacology (2008) 154, 1287–1296; doi:10.1038/bjp.2008.186; published online 19 May 2008
Autoradiographic characterization of α2C‐adrenoceptors in the human striatum
Indirect experimental evidence suggests that drugs acting on the α2C‐adrenoceptor could be useful in the treatment of neuropsychiatric disorders such as depression and schizophrenia. In rodent brain, the highest levels of α2C‐adrenoceptors are found in the striatum, with lower levels in cerebral cortex and hippocampus. In human brain, because of the poor subtype‐selectivity of the available α2‐adrenoceptor ligands, the localization of α2C‐adrenoceptors has remained unknown. Recently, a selective α2C‐adrenoceptor antagonist, JP‐1302, was characterized, and to assess the presence of α2C‐adrenoceptors in human brain, we performed competition binding in vitro receptor autoradiography with JP‐1302 and the α2‐adrenoceptor subtype nonselective antagonist [ethyl‐3H]RS79948‐197 on rat and human postmortem brain sections. In striatum of both species, JP‐1302 vs. [ethyl‐3H]RS79948‐197 competition binding was biphasic, identifying high‐ and low‐affinity binding sites, whereas in cortex and cerebellum, only low‐affinity binding sites were detected. The results indicate that a significant portion of the α2‐adrenoceptors in striatum is of the α2C subtype, whereas non‐α2C‐adreocneptors predominate in cortex and cerebellum. Because the α2C‐adrenoceptor subtype distribution pattern appears to be conserved between rodents and humans, results obtained from studies on the role of the α2C‐adrenoceptor in rodent models of neuropsychiatric disorders may be relevant also for human diseases. Synapse 62:508–515, 2008.
Autoradiographic characterization of α2C‐adrenoceptors in the human striatum
Indirect experimental evidence suggests that drugs acting on the α2C‐adrenoceptor could be useful in the treatment of neuropsychiatric disorders such as depression and schizophrenia. In rodent brain, the highest levels of α2C‐adrenoceptors are found in the striatum, with lower levels in cerebral cortex and hippocampus. In human brain, because of the poor subtype‐selectivity of the available α2‐adrenoceptor ligands, the localization of α2C‐adrenoceptors has remained unknown. Recently, a selective α2C‐adrenoceptor antagonist, JP‐1302, was characterized, and to assess the presence of α2C‐adrenoceptors in human brain, we performed competition binding in vitro receptor autoradiography with JP‐1302 and the α2‐adrenoceptor subtype nonselective antagonist [ethyl‐3H]RS79948‐197 on rat and human postmortem brain sections. In striatum of both species, JP‐1302 vs. [ethyl‐3H]RS79948‐197 competition binding was biphasic, identifying high‐ and low‐affinity binding sites, whereas in cortex and cerebellum, only low‐affinity binding sites were detected. The results indicate that a significant portion of the α2‐adrenoceptors in striatum is of the α2C subtype, whereas non‐α2C‐adreocneptors predominate in cortex and cerebellum. Because the α2C‐adrenoceptor subtype distribution pattern appears to be conserved between rodents and humans, results obtained from studies on the role of the α2C‐adrenoceptor in rodent models of neuropsychiatric disorders may be relevant also for human diseases. Synapse 62:508–515, 2008.